Clinical Trial Results:
            A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia.
    
|     Summary | |
|     EudraCT number | 2008-001550-41 | 
|     Trial protocol | FR CZ DE SE ES HU BE DK PT PL NL | 
|     Global completion date | 
                                    17 Jun 2009
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    29 Oct 2016
                             | 
|     First version publication date | 
                                    29 Oct 2016
                             | 
|     Other versions | |
|     Summary report(s) | EFC6910 | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
